An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults by unknown
ORIGINAL RESEARCH ARTICLE
An Open-Label Investigation of the Pharmacokinetic Profiles
of Lisdexamfetamine Dimesylate and Venlafaxine
Extended-Release, Administered Alone and in Combination,
in Healthy Adults
James Ermer • Mary B. Haffey • Cynthia Richards • Kenneth Lasseter • Benno Roesch •
Jaideep Purkayastha • Mary Corcoran • Bree Harlin • Patrick Martin
Published online: 20 March 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background Lisdexamfetamine dimesylate (LDX), a
prodrug consisting of d-amphetamine and l-lysine, is being
studied in clinical trials of major depressive disorder.
Additional drug-drug interaction studies were warranted.
Objective This study aimed to describe the pharmacoki-
netics and safety of LDX and venlafaxine extended-release
(VXR), alone or combined.
Study Design The study was an open-label, two-arm,
single-sequence crossover investigation with randomiza-
tion to treatment sequence.
Setting and Participants The study was conducted at two
clinical study centres and included healthy adult males and
females (18–45 years of age).
Intervention The study included two single-sequence
crossover designs: LDX alone followed by LDX ? VXR
(Treatment Arm A); and VXR alone followed by
VXR ? LDX (Treatment Arm B). Drug treatment was
initiated on day 1 with once-daily LDX or VXR alone with
15 days’ titration to final dose (LDX 30, 50 and 70 mg for
5 days each; VXR 75, 150 and 225 mg for 5 days each).
On days 16–30, VXR, titrated to a final dose of 225 mg, or
LDX, titrated to a final dose of 70 mg, was coadministered
for participants in Treatment Arm A or B, respectively. On
days 31–38, VXR doses were tapered.
Main Outcome Measures On days 1–2, 15–16 and 30–31,
safety evaluations and blood samples were obtained pre-
dose through 24 h post-dose for analysis of LDX,
d-amphetamine, venlafaxine (VEN), and O-des-
methylvenlafaxine (ODV). Combination treatment was
considered bioequivalent to single treatment if 90 % confi-
dence intervals (CIs) for geometric mean ratios (GMRs) of
analytes fell within the interval 0.80–1.25 based on maximum
plasma concentration (Cmax) and area under the plasma
concentration-time curve (AUC) from time zero to time of
last measurable concentration (AUCs). Safety assessments
included treatment-emergent adverse events (TEAEs), pulse
rate and blood pressure (BP), clinical laboratory assessments,
and 12-lead electrocardiograms (ECG).
Results Among 80 enrolled subjects, 77 were included in
pharmacokinetic and safety analyses. Combination
LDX ? VXR was bioequivalent to LDX alone, based on
exposure to d-amphetamine (GMR [95 % CI], Cmax (ng/
mL): 0.97 [0.82, 1.14], AUCs: 0.95 [0.81, 1.12]). Exposure
to VEN with LDX ? VXR (vs. VXR alone) was increased
(Cmax: 1.10 [0.88, 1.38], AUCs: 1.13 [0.88, 1.45]) and
ODV decreased (Cmax: 0.91 [0.77, 1.06], AUCs: 0.83 [0.71,
0.96]), whereas composite VEN ? ODV was bioequiva-
lent to VXR alone (Cmax: 0.96 [0.84, 1.09], AUCs: 0.98
[0.85, 1.13]). TEAEs with LDX or LDX ? VXR were
similar. Maximum mean increases from baseline were:
pulse rate, ?8.73 to 12.76 beats/min with either treatment
alone and ?17.67 to 20.85 beats/min with LDX ? VXR;
systolic BP, ?4.32 to 6.56 mmHg with either treatment
alone and ?12.96 to 13.78 mmHg with LDX ? VXR;
diastolic BP, ?5.39 to 5.74 mmHg with either treatment
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alone and ?12.09 to 12.46 mmHg with LDX ? VXR. One
participant was withdrawn due to a serious TEAE (pre-
syncope). No unexpected, clinically meaningful trends or
changes from baseline in mean laboratory or ECG
parameters were observed during the trial.
Conclusion In healthy adults, combination LDX ? VXR
(vs. LDX alone) did not alter exposure to d-amphetamine.
Although small changes in exposure to VEN (increased)
and ODV (decreased) were seen with combination treat-
ment, total VEN ? ODV exposure showed no change (vs.
VEN alone). LDX ? VXR led to increases in BP and pulse
rate, supporting existing recommendations for vital sign
monitoring when using these medications.
1 Introduction
Lisdexamfetamine dimesylate (LDX) is a long-acting
prodrug of dextroamphetamine (d-amphetamine) and is
approved for the treatment of attention-deficit/hyper-
activity disorder in children (6–12 years), adolescents
(13–17 years) and adults [1]. After oral administration,
active d-amphetamine is released via enzyme-mediated
biotransformation [2]. The investigation of LDX in clinical
trials for major depressive disorder [3, 4] indicated a need
for additional information about pharmacokinetics and
safety, including the potential for drug-drug interactions.
LDX does not inhibit any cytochrome P450 (CYP) iso-
enzyme tested to date [5], but its active component,
d-amphetamine, weakly inhibits CYP2D6 activity [1].
In vitro studies suggest that exposure to amphetamine or its
metabolites, as would follow LDX administration, might
inhibit the CYP enzymes CYP2D6, CYP1A2 and CYP3A4
[1, 6], raising the possibility of drug-drug interactions. The
CYP family of isoenzymes is also primarily responsible for
the metabolism of several key medications used to treat
patients with indications of interest in the LDX research
programme [7, 8]. Coadministration of LDX with com-
pounds for which these CYP enzymes play a metabolic role
could potentially alter the pharmacokinetics of one or both
drugs, marked by prolonged clearance, increased maximum
plasma concentrations, and increased overall exposure.
Venlafaxine extended-release (VXR), a selective sero-
tonin-norepinephrine reuptake inhibitor (SNRI), is indi-
cated for treatment of major depressive disorder, as well as
generalized and social anxiety disorders and panic disorder
[9]. Venlafaxine (VEN), the active component of VXR, is
metabolized to active O-desmethylvenlafaxine (ODV) by
CYP2D6 [10], making it a useful substrate by which to test
for potential interaction of LDX with the CYP2D6 system.
Coadministration of VXR with LDX may lead to changes
in VEN metabolism, potentially marked by increased
exposure to VEN. Moreover, in adults, VEN exerts well-
characterized effects on cardiovascular functioning,
marked by modest mean increases in blood pressure and
heart rate. In a small number of individual patients (i.e.,
0.7–1.3 %), larger sustained increases in blood pressure
have led to treatment discontinuation [9, 11]. Mean
increases in blood pressure and heart rate have also been
observed in adults following administration of clinically
optimized doses of LDX and other d-amphetamine- or
methylphenidate-containing medications [1, 12–14], rais-
ing the possibility that combination LDX/VXR treatment
may potentiate these cardiovascular effects. It is, therefore,
of particular interest to carefully examine vital sign
parameters during coadministration of these drugs.
The primary objective of the present investigation in
healthy adults was to characterize the pharmacokinetics of
the prodrug LDX and LDX-derived d-amphetamine and
VEN and its active metabolite, ODV, when LDX and VXR
were administered alone and in combination. A secondary
objective was to examine the safety of combination




This study of LDX was an open-label, two-arm, single-
sequence crossover investigation with randomization to
treatment sequence investigation in healthy adults, con-
sisting of a screening period, a 38-day treatment period,
and safety telephone follow-up. There were two treatment
arms: A (initial titration with LDX over 15 days followed
by the addition of VXR, titrated over an additional
15 days) and B (initial titration with VXR over 15 days
followed by the addition of LDX, titrated over an addi-
tional 15 days). During pre-dose baseline assessments,
participant blood samples were obtained for CYP2D6
genotyping. To minimize the potential for adverse effects
during initiation of treatment with either LDX (e.g., diz-
ziness, palpitations) or VXR (e.g., nausea, vomiting), doses
were gradually titrated upward at 5-day intervals to maxi-
mal doses of LDX 70 mg/day and VXR 225 mg/day; at the
end of the study, VXR doses were also gradually decreased
over a 1-week period. Figure 1 illustrates the dosing/titra-
tion schedule for each of the treatment arms and scheduled
study assessments. On day -2 through day 2 and day 14
through day 31, participants remained at one of two clinical
study centres (CSCs); on other days, participants made
daily visits to the same CSC.
The study was approved by the Independent Investiga-
tional Review Board, Inc (Plantation, FL, USA) and was
conducted in accordance with the principles of the
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Declaration of Helsinki and its amendments, all local eth-
ical and legal requirements, as well as US Food and Drug
Administration (FDA) guidance on appropriate conduct of
in vivo drug-drug interaction studies [15]. All participants
were required to provide signed informed consent prior to
performance of any study-related procedures and a separate
consent for genotyping sampling.
2.2 Key Inclusion/Exclusion Criteria
This study enrolled healthy adult male and non-pregnant,
non-lactating females (aged 18–45 years). Participants
were excluded if they had any current or recurrent disease
that could affect the absorption, disposition or effect of the
investigational products, or clinical or laboratory assess-
ments; medical or psychiatric illness that might require
treatment, affect ability to comply with investigational
protocol, or present undue risk; history of significant anx-
iety or agitation; current diagnosis or history of glaucoma;
current diagnosis or history of a tic disorder, or personal/
family history of Tourette’s disorder; structural cardiac
abnormality, transient ischaemic attack or stroke, or any
other serious cardiac condition; history of hypertension, or
high blood pressure at screening (systolic blood pressure
[SBP] [139 mmHg and/or diastolic blood pressure [DBP]
[89 mmHg, taken at rest while sitting); family history of
sudden cardiac death or ventricular arrhythmia; history of
alcohol or other substance abuse within the past year; a
positive screen for drugs of abuse or alcohol during the
screening visit or check-in; and consumption of alcohol
within 7 days, or caffeine/xanthine-containing products
within 24 h of the first study medication dose or during the
study. Also excluded were individuals who had smoked or
used nicotine-containing products within 30 days prior to
the first dose of study medication or during the study, as
well as those who had donated blood or blood products
(e.g., plasma, platelets) within 60 days or had received
another investigational product within 30 days prior to the
first dose of study medication.
2.3 Study Medication Administration
Study medication was administered with 240 mL room
temperature water; dosing occurred on the scheduled days
at the study clinic throughout the investigation period.
Capsules were swallowed whole, not cut, chewed or cru-
shed. On days of serial blood sampling (days 1, 15 and 30),
study medication was administered following a fast of
approximately 10 h, and food was not given until 4 h post-
dosing. Water intake was restricted for 4 h prior to dosing
and 2 h following dosing.
2.4 Blood Sampling and Analysis
During baseline assessments, participant blood samples
were obtained for CYP2D6 genotyping. For pharmacoki-
netic analysis, serial blood samples were collected up to
24 h after dose administration on days 1, 15 and 30; on
these study days, samples were obtained pre-dose (at
-0.5 h) and at the following times post-dose: 0.5, 1, 1.5, 2,
3, 4, 6, 8, 9, 12 and at 0/24 h on days 2, 16, and 31. On days
14 and 29, a single blood sample was obtained at 0.5 h pre-
dose. Plasma concentrations of LDX, d-amphetamine,
VEN and ODV were measured using validated liquid
chromatography with tandem mass spectrometry (LC-MS/
MS) methods. Samples from days on which participants
were dosed with LDX alone were analysed for LDX and
d-amphetamine only; samples from days on which partic-
ipants were dosed with VXR alone were analysed for VEN
and ODV only; and samples from days on which partici-
pants were dosed with both LDX and VXR were analysed
for LDX, d-amphetamine, VEN and ODV. Briefly, LDX,
d-amphetamine, VEN and ODV concentrations in human
plasma were determined using a LC-MS/MS method val-
idated over the range of 1–100 ng/mL for LDX and
2–200 ng/mL for d-amphetamine; over the range of
0.5–250 ng/mL for VEN and 1–500 ng/mL for ODV all
based on 200 lL of human plasma. Human plasma con-
taining LDX, d-amphetamine, VEN and ODV, and internal
Fig. 1 Timing of study visits, and procedures. LDX lisdexamfetamine dimesylate, VXR venlafaxine extended-release
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standards, D8-LDX, D5-amphetamine or D6-VEN and D6-
ODV, was extracted with ethyl acetate/toluene (1:1) in the
presence of saturated sodium chloride/sodium hydroxide
for LDX/d-amphetamine and with ethyl acetate in sodium
phosphate buffer for VEN/ODV. Following centrifugation,
the organic layer was transferred and evaporated. After the
addition of formic acid for LDX/d-amphetamine and ethyl
acetate for VEN/ODV and reconstitution in mobile phase,
an aliquot was injected onto a AB SCIEX APITM 4000 LC-
MS/MS (Framingham, MA, USA) equipped with a high-
performance liquid chromatography column. The peak area
of the m/z 264 ? 84 LDX product ion was measured
against the peak area of the m/z 272 ? 92 D8-LDX
internal standard product ion. The peak area of the m/z
136 ? 91 amphetamine product ion was measured against
the peak area of the m/z 141 ? 96 D5-amphetamine
internal standard product ion. The peak area of the m/z
278 ? 58 VEN product ion was measured against the peak
area of the m/z 284 ? 58 D6-VEN internal standard
product ion. The peak area of the m/z 264 ? 58 ODV
product ion was measured against the peak area of the m/z
270 ? 58 D6-ODV internal standard product ion. Peak
area integrations were performed using Analyst software
(version 1.4.2) from Applied Biosystems (Carlsbad, CA,
USA). Concentrations were calculated using 8-point curves
ranging from 1 to 100 ng/mL for LDX and 2 to 200 ng/mL
for d-amphetamine with separate weighted linear regres-
sion; ranging from 0.5 to 250 ng/mL for VEN and 1 to
500 ng/mL for ODV with separate weighted linear
regression. Based on a sample volume of 200 lL, the
method had a lower limit of quantification of 1 ng/mL for
LDX and 2 ng/mL for d-amphetamine; 0.5 ng/mL for VEN
and 1 ng/mL for ODV. Values below this limit were
reported as not quantifiable.
Pharmacokinetic parameters were determined from the
plasma concentration-time data for LDX, d-amphetamine,
VEN, ODV and composite (VEN ? ODV) by non-com-
partmental analysis. The following pharmacokinetic
parameters were calculated from plasma concentrations of
d-amphetamine, LDX, VEN and ODV: maximum plasma
concentration (Cmax), time to reach Cmax (tmax), area under
the plasma concentration-time curve (AUC) from time
zero to time of last measurable concentration (AUCs),
elimination half-life (t) and relative bioavailability. Var-
iability was assessed with percent coefficient of variation
(% CV).
2.5 Safety Assessments
Safety was evaluated based on reported treatment-emer-
gent adverse events (TEAEs), assessed at regular intervals
throughout the study and coded using the Medical Dictio-
nary for Regulatory Activities (MedDRA), version 11.1,
and by assessing the scheduled physical examination
findings, vital signs (including pulse rate and blood pres-
sure), clinical laboratory parameters and electrocardio-
grams (ECGs).
2.6 Statistical Analysis
To demonstrate bioequivalence (in each arm), 24 subjects
were needed in each treatment arm to achieve 90 % power
based on allowing for a 5 % difference in true means and
the true within-subject SD (based on the higher of the AUC
SDs between LDX and VXR) being C0.20.
The safety analysis set was defined as all participants
who received at least one dose of study medication and had
at least one post-dose safety assessment. Pharmacokinetic
parameters were analysed based on the pharmacokinetics
analysis set, defined as all participants who received at
least one dose of study medication, had at least one post-
dose safety assessment, had no major protocol deviations
related to intake of study medication (e.g., vomiting), and
for whom the primary pharmacokinetic data were consid-
ered sufficient and interpretable. For each treatment arm,
summary descriptive statistics were determined for all
pharmacokinetic parameters as well as plasma concentra-
tions of LDX, d-amphetamine, VEN and ODV at each
scheduled sampling time. For each treatment arm, the
means of log-transformed pharmacokinetic parameters
were compared using mixed effects analysis of variance.
To estimate the magnitude of difference in Cmax and AUCs
for LDX and d-amphetamine between LDX alone and
LDX ? VXR (Treatment Arm A) and for VEN, ODV and
total VEN ? ODV between VXR alone and LDX ? VXR
(Treatment Arm B), geometric mean ratios (GMRs) and
their 90 % confidence intervals (CIs) were calculated.
Combination LDX ? VXR was considered not to have an
interaction if the 90 % CIs for GMRs of analytes fell
within the interval 0.80–1.25 based on Cmax and AUCs.
3 Results
3.1 Disposition and Demographics
A total of 175 participants were screened; 80 healthy adults
were randomized and enrolled (n = 42, Treatment Arm A;
n = 38, Treatment Arm B) (Fig. 2) and 64 completed the
study. Seventy-seven participants were included in the
pharmacokinetic and safety analysis sets. Of the 16 par-
ticipants who discontinued, 11 (26.2 %) discontinued from
Treatment Arm A and 5 (13.2 %) discontinued from
Treatment Arm B. The most common reasons for discon-
tinuation were AEs (n = 5) and withdrawal of consent
(n = 5).
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For participants in the safety analysis set, mean (SD) age
at baseline was 33.5 (7.10) years, 55 (71.4 %) participants
were men, and 56 (72.7 %) participants were white
(Table 1). Mean (SD) weight was 75.0 kg (11.81), and
mean (SD) body mass index was 25.5 kg/m2 (2.75).
Genotyping conducted at baseline revealed that most par-
ticipants were extensive (n = 59) or intermediate (n = 16)
CYP2D6 metabolizers; two participants were CYP2D6
poor metabolizers (both in Treatment Arm A).
3.2 LDX and d-Amphetamine Pharmacokinetic
Analysis
The 24-h post-dose plasma concentration over time profiles
for LDX and LDX-derived d-amphetamine on day 1
(beginning of titration), day 15 (end of titration), and day
30 (end of LDX ? VXR coadministration) are shown in
Fig. 3a, b, respectively. LDX and d-amphetamine phar-
macokinetic parameters for days 15 and 30 are summarized
in Table 2. LDX and d-amphetamine pharmacokinetic
profiles were similar regardless of whether LDX was given
alone (day 15) or combined with VXR (day 30) (Table 2).
Standard bioequivalence criteria (interval 0.80–1.25) [16]
confirmed that systemic exposure to d-amphetamine (based
on Cmax and AUCs) was similar for LDX given alone or in
combination with VXR (Table 3).
3.3 Venlafaxine and ODV Pharmacokinetic Analysis
The 24-h post-dose plasma concentration over time profiles
for VEN, ODV and total VEN ? ODV on day 1 (begin-
ning of titration), day 15 (end of titration) and day 30 (end
of LDX ? VXR coadministration) are shown in Fig. 4a–c,
respectively. VEN, ODV and total VEN ? ODV pharma-
cokinetic parameters for days 15 and 30 are summarized in
Table 2. For combination LDX ? VXR compared with
VXR alone, VEN Cmax, AUCs and t were slightly lower
compared with VXR given alone for Treatment Arm A
(LDX 70 mg/day ? VXR 225 mg/day) and slightly higher
for Treatment Arm B (VXR 225 mg/day ? LDX 70 mg/
day) (Table 2). ODV Cmax and AUCs were lower for both
Fig. 2 Participant disposition.
Treatment Arm A initial LDX
alone, followed by combination
LDX ? VXR; Treatment Arm B
initial VXR alone, followed by
combination LDX ? VXR.










(n = 40) (n = 37) (n = 77)
Age, years
[mean (SD)]
33.2 (7.01) 33.8 (7.29) 33.5 (7.10)
Male [n (%)] 28 (70.0) 27 (73.0) 55 (71.4)
Weight, kg
[mean (SD)]
75.5 (12.09) 74.5 (11.64) 75.0 (11.81)
BMI, kg/m2
[mean (SD)]
25.5 (2.83) 25.5 (2.70) 25.5 (2.75)
Race [n (%)]
White 31 (77.5) 25 (67.6) 56 (72.7)
Non-white 9 (22.5) 12 (32.4) 21 (27.3)
BMI body mass index, LDX lisdexamfetamine dimesylate, VXR
venlafaxine extended-release
a Treatment Arm A = initial LDX alone, followed by combination
LDX 70 mg/day ? VXR 225 mg/day
b Treatment Arm B = initial VXR alone, followed by combination
LDX 70 mg/day ? VXR 225 mg/day
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treatment arms, although t was shorter for Treatment Arm
A and longer for Treatment Arm B with combination
LDX ? VXR, compared with VXR alone (Table 2). Total
VEN ? ODV Cmax and AUCs were slightly lower and t
was slightly longer with combination LDX ? VXR com-
pared with VXR alone. The results of bioequivalence
testing, summarized in Table 3, showed that systemic
exposure to VEN was increased, to ODV was decreased
and to total VEN ? ODV unaltered, given combination
LDX ? VXR, compared with VXR alone.
3.4 Pharmacokinetics in CYP2D6 Poor Metabolizers
One of two CYP2D6 poor metabolizers withdrew prema-
turely from the study (due to an AE of depressed mood)
and did not receive VXR. The remaining poor metabolizer
completed the study and exhibited higher individual VEN
plasma concentrations and lower ODV plasma concentra-
tions at day 30 than all other participants at this time point.
This participant’s total VEN ? ODV plasma concentra-
tions were similar to those seen in other participants.
3.5 Safety
TEAEs with LDX or VXR treatment alone are summarized
in Table 4. One participant (male, Treatment Arm A) had a
serious AE (presyncope) on day 5 of the dose-titration
period of the study (LDX 30 mg/day at time of TEAE
onset); the event, considered related to study medication,
resolved within 10 min. Prior to this event, the subject
reported several TEAEs (somnolence, palpitations, erectile
dysfunction, anorexia) during LDX titration; he was dis-
continued from the trial.
Changes from baseline blood pressure and pulse rate are
shown in Table 5 and Fig. 5a–c. Maximum mean increases
in pulse rate, SBP and DBP in Treatment Arm A (LDX
alone) were approximately 13 beats/min, 7 mmHg and
6 mmHg, respectively. Maximum mean increases in pulse
rate, SBP and DBP in Treatment Arm B (VXR alone) were
approximately 9 beats/min, 4 mmHg and 5 mmHg,
respectively. Maximum mean increases in pulse rate, SBP
and DBP with combination treatment in Treatment Arm A
(LDX ? VXR) were approximately 18 beats/min,
13 mmHg and 12 mmHg, respectively, and with combi-
nation treatment in Treatment Arm B (VXR ? LDX) were
approximately 21 beats/min, 14 mmHg and 12 mmHg,
respectively. No participant was discontinued due to a
change in vital signs.
No clinically meaningful laboratory or ECG results or
changes from baseline were observed during the trial
among participants in either treatment arm, with the
exception of a female participant aged 24 years in Treat-
ment Arm B. At 2 h post-dose on days 15 (VXR 225 mg/
day) and 30 (VXR 225 mg/day ? LDX 70 mg/day) this
participant exhibited what the investigator considered
clinically abnormal ECG results for heart rate, PR interval,
QRS duration, QT interval and corrected QT obtained
using Bazett’s formula (QTcB) interval. On both occa-
sions, all ECG parameters returned to normal readings at
4 h.
4 Discussion
With LDX being studied in clinical trials with more med-
ically diverse clinical populations, it was necessary to
examine the safety and risk for drug-drug interactions of
LDX coadministered with medications commonly used in
Fig. 3 Mean (SD) plasma concentration versus time plots for a LDX
and b d-amphetamine, following administration of LDX 30 mg/day
(day 1, beginning of titration), LDX 70 mg/day (day 15, end of
titration), and LDX 70 mg/day ? VXR 225 mg/day (day 30, end of
coadministration). LDX lisdexamfetamine dimesylate, VXR venlafax-
ine extended-release
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Table 3 Bioequivalence test results
Analyte Treatment arm Geometric least squares means Test/reference ratio [90 % CI]
LDX alone Day 15 VXR alone Day 15 LDX ? VXR Day 30
d-Amphetamine A –
AUCs (ngh/mL) 1,112 1,057 0.95 [0.806, 1.121]
Cmax (ng/mL) 85.87 83.03 0.967 [0.821, 1.139]
VEN B –
AUCs (ngh/mL) 2,407 2,719 1.129 [0.88, 1.45]
Cmax (ng/mL) 180.7 199.2 1.103 [0.881, 1.38]
ODV B –
AUCs (ngh/mL) 8,083 6,676 0.826 [0.713, 0.956]
Cmax (ng/mL) 391.5 354.9 0.907 [0.777, 1.058]
Total VEN ? ODV B –
AUCs (ngh/mL) 10,128 9,894 0.977 [0.848, 1.126]
Cmax (ng/mL) 593.1 567.4 0.957 [0.84, 1.089]
AUCs area under the plasma concentration time curve from time zero to time of last measurable concentration, CI confidence interval, Cmax




after LDX alone, VXR alone
(day 15) or combination
LDX ? VXR (day 30)
Data are given as mean (SD)
Treatment Arm A = initial
LDX alone, followed by
combination LDX 70 mg/
day ? VXR 225 mg/day;
Treatment Arm B = initial
VXR alone, followed by
combination LDX 70 mg/
day ? VXR 225 mg/day
AUCs area under the plasma
concentration time curve from


















LDX alone 49.1 (32.25) 1.1 (0.3) 65.5 (44.0) 0.4 (0.1)
Combinationa
Arm A 49.8 (34.3) 1.1 (0.3) 63.9 (43.7) 0.4 (0.1)
Arm B 50.8 (19.68) 1.0 (0.3) 60.8 (19.2) 0.4 (0.2)
d-Amphetamine
LDX alone 88.9 (26.9) 3.5 (1.5) 1,143.4 (292.8) 10.4 (1.8)
Combinationa
Arm A 88.9 (22.7) 3.2 (1.0) 1,135.4 (301.5) 9.8 (1.7)
Arm B 85.3 (20.6) 3.1 (1.3) 1,049.2 (268.7) 9.7 (2.1)
VEN
VXR alone 211.0 (120.6) 6.4 (0.8) 2,900.0 (1,919.3) 10.8 (2.7)
Combinationa
Arm A 198.5 (105.48) 6.0 (1.3) 2,839.7 (1,706.8) 10.7 (2.4)
Arm B 228.9 (124.42) 5.9 (0.6) 3,202.6 (1,942.5) 11.2 (3.1)
ODV
VXR alone 420.6 (139.67) 7.9 (1.2) 8,363.3 (2,168.1) 19.5 (6.0)
Combinationa
Arm A 413.7 (150.0) 8.5 (1.7) 8,061.3 (2,868.7) 18.3 (4.4)
Arm B 371.5 (104.9) 7.9 (1.3) 6,955.1 (1,962.8) 20.9 (6.7)
Total VEN ? ODV
VXR alone 624.6 (179.7) 7.3 (1.1) 10,738.0 (3,273.3) 16.9 (4.3)
Combinationa
Arm A 603.5 (181.3) 7.1 (1.4) 10,673.9 (3,035.7) 17.9 (4.9)
Arm B 588.7 (158.8) 7.0 (1.2) 10,342.2 (3,096.1) 18.4 (5.6)
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psychiatric practice. For this study, pharmacokinetic and
safety profiles of LDX given alone and in combination with
the antidepressant VXR were described in healthy adults.
Combination LDX ? VXR did not alter exposure to
d-amphetamine (vs. LDX alone). Although small changes
in exposure to VEN (increased) and ODV (decreased) were
seen, total VEN ? ODV exposure showed no change with
combination treatment (vs. VXR alone) as demonstrated by
bioequivalence testing. Changes from baseline in pulse rate
and blood pressure were greater in magnitude during
coadministration compared with either drug being admin-
istered alone. The TEAE profile with coadministration was
similar to that when LDX was given alone.
LDX does not inhibit any CYP isoenzymes tested to
date [5], but its active component, d-amphetamine, weakly
inhibits CYP2D6 activity [1, 6]. CYP2D6 is the enzyme
Fig. 4 Mean (SD) plasma concentration versus time plots for a VEN,
b ODV and c composite VEN ? ODV following administration of
VXR 75 mg/day (day 1, beginning of titration), VXR 225 mg/day
(day 15, end of titration), and LDX 70 mg/day ? VXR 225 mg/day
(day 30, end of coadministration). LDX lisdexamfetamine dimesylate,
ODV O-desmethylvenlafaxine, VEN venlafaxine
Table 4 Frequency C5 % of TEAEs [n (%)] associated with study







Any TEAE 33 (82.5) 25 (67.6) 46 (68.7)
Anorexia 12 (30.0) 9 (24.3) 0 (0.0)
Anxiety 5 (12.5) 0 (0.0) 2 (3.0)
Back pain 2 (5.0) 0 (0.0) 0 (0.0)
Chest pain 3 (7.5) 0 (0.0) 1 (1.5)
Constipation 3 (7.5) 3 (8.1) 11 (16.4)
Diarrhoea 2 (5.0) 3 (8.1) 2 (3.0)
Dizziness 3 (7.5) 4 (10.8) 7 (10.4)
Dry mouth 10 (25.0) 7 (18.9) 6 (9.0)
Dyspnoea 2 (5.0) 0 (0.0) 1 (1.5)
Epistaxis 0 (0.0) 0 (0.0) 5 (7.5)
Euphoric mood 3 (7.5) 0 (0.0) 0 (0.0)
Headache 7 (17.5) 6 (16.2) 13 (19.4)
Insomnia 7 (17.5) 3 (8.1) 5 (7.5)
Libido decreased 0 (0.0) 2 (5.4) 0 (0.0)
Nausea 6 (15.0) 7 (18.9) 4 (6.0)
Palpitations 8 (20.0) 0 (0.0) 2 (3.0)
Somnolence 7 (17.5) 7 (18.9) 0 (0.0)
Stomach discomfort 2 (5.0) 0 (0.0) 0 (0.0)
Testicular pain 0 (0.0) 0 (0.0) 5 (7.5)
Urinary hesitation 0 (0.0) 1 (2.7) 5 (7.5)
Vision blurred 2 (5.0) 0 (0.0) 0 (0.0)
LDX lisdexamfetamine dimesylate, VXR venlafaxine extended-
release, TEAE treatment-emergent adverse event
a Data for VXR alone and LDX alone = TEAEs reported during
dose titration periods
b The 67 participants in the combination group consisted of those
receiving at least one dose of LDX ? VXR in Treatment Arm A (32
participants) and VXR ? LDX in Treatment Arm B (35 participants)
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primarily responsible for the metabolism of various anti-
depressant and second-generation antipsychotic medica-
tions [7, 8]. Because VEN is primarily metabolized to
active ODV via O-demethylation that is dependent on
CYP2D6 isoenzyme activity (to a lesser degree, it is
metabolized via CYP3A4-dependent N-demethylation
[10]), VXR was chosen as a representative compound to
test potential for interaction with LDX. The current phar-
macokinetic findings confirm that d-amphetamine is a
weak inhibitor of CYP2D6 activity. With LDX ? VXR
coadministration, slight but statistically significant increa-
ses in VEN exposure and slight decreases in ODV exposure
were observed. The clinical impact of such changes is
likely not significant. Both VEN and ODV are pharmaco-
logically active, with similar neurotransmitter receptor
affinity profiles [9]. Moreover, with LDX ? VXR coad-
ministration, exposure to the two active compounds
(VEN ? ODV) taken together was unchanged. Given these
facts, the observed small changes in VEN and ODV
pharmacokinetics are not expected to alter VXR-mediated
clinical outcomes.
As expected, the single poor CYP2D6 metabolizer who
completed the study exhibited higher levels of VEN and
lower levels of ODV than were seen in the other partici-
pants who were extensive or intermediate metabolizers;
total VEN ? ODV exposure, however, was similar to the
overall group mean. This finding highlights the potential
clinical importance of d-amphetamine-mediated CYP2D6
inhibition for individuals receiving LDX in combination
with other medications. The small pharmacokinetic chan-
ges currently observed with LDX ? VXR coadministra-
tion do not rule out the possibility of clinically significant
pharmacokinetic alterations when LDX is administered in
combination with other compounds. Further research may
be required to determine the potential for drug–drug
interactions between LDX and other widely prescribed
compounds that are metabolized predominantly via
CYP2D6 activity [10] or which also inhibit CYP2D6
enzyme activity.
Safety observations with LDX ? VXR coadministration
were in line with expectations. The most common TEAEs
reported with combination treatment were generally similar
to those seen with LDX alone. As expected, common
TEAEs with VXR alone included anorexia, dry mouth,
nausea, somnolence and headache; with LDX alone, these
included dry mouth, anorexia and palpitations. Also as
expected, with either LDX alone or VXR alone, small
mean increases in pulse rate and blood pressure occurred,
and these increases were greater in magnitude when LDX
and VXR were coadministered. As illustrated in Fig. 5a–c,
these increases tended to emerge gradually over several
days; no participant was discontinued due to an increase in
pulse rate or blood pressure.
The present investigation had several limitations that
warrant consideration. The sample comprised primarily
healthy adult white men; thus, findings might not be gen-
eralizable to younger or older individuals, adults with
medical or psychiatric co-morbidities, those of other racial
or ethnic backgrounds, or women. LDX and VXR were
coadministered at their maximum approved therapeutic
doses (LDX 70 mg/day and VXR 225 mg/day); changes in
VEN and ODV pharmacokinetics were not characterized
using different (i.e., lower or higher) LDX and VXR doses.
This study examined pharmacokinetics and safety during
short-term coadministration of LDX ? VXR; pharmaco-
kinetics and safety with longer-term combination treatment
are unknown. Comparison of data on vital signs to data
gathered from previous outpatient clinical trials (summa-
rized in the respective product information of LDX [1] and
VXR [9]) should consider limitations due to several fac-
tors: (i) participants were housed for a relatively long time
period in a CSC where normal routines of diet, activity and
exercise were disrupted; (ii) LDX and VXR were tested in
combination only at the highest recommended doses; and
(iii) monitoring of vital signs in outpatient clinical trials
occurs at various times of the day, whereas in the current
trial vital signs were recorded according to a well-defined
schedule, relative to time of dosing and time course of
Table 5 Range (1–2 h post-dose) of mean change from time-matched baselinea in vital signs over 1–12 h post-dose
Vital signs Treatment Arm A Treatment Arm B Combination
LDX alone VXR alone LDX ? VXRb
Pulse rate (beats/min) -0.78c to 12.76 -3.73 to 8.73 4.66–20.85
Systolic blood pressure (mmHg) -0.77c to 6.56 -0.52 to 4.32 4.44c to 13.78
Diastolic blood pressure (mmHg) 0.57c to 5.74 1.18–5.39 7.05–12.46
LDX lisdexamfetamine dimesylate, VXR venlafaxine extended-release
a Baseline was defined as the time-matched measurement at day -1 for each treatment period
b Includes subjects who received LDX ? VXR in Treatment Arm A as well as those who received VXR ? LDX in Treatment Arm B
c Value occurred at first post-dose measurement (1 h post-dose)
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Fig. 5 Mean (SD) changea from baseline in a pulse rate, b systolic blood pressure and c diastolic blood pressure on day 1 (beginning of
titration), day 15 (end of titration) and day 30 (end of coadministration). LDX lisdexamfetamine dimesylate, VXR venlafaxine extended-release
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plasma drug levels. Despite these limitations, the current
study provides useful information to help clinicians
develop appropriate procedures for dosing and safety
monitoring when LDX is coadministered with VXR in a
diverse adult population. As with each agent alone, moni-
toring of vital signs (pulse rate, blood pressure) is recom-
mended should LDX and VXR be coadministered.
5 Conclusion
In healthy adults, combination LDX ? VXR (vs. LDX
alone) did not alter exposure to d-amphetamine. Although
small changes in exposure to VEN (increased) and ODV
(decreased) were seen with combination treatment, sup-
porting evidence that d-amphetamine is a weak inhibitor of
CYP2D6 activity, total VXR ? ODV exposure showed no
change (vs. VEN alone). Increases in pulse rate and blood
pressure observed when LDX and VEN were administered
alone were consistent with previous studies [11, 13, 17].
Changes from baseline in vital signs were greater in
magnitude during coadministration compared with when
either LDX or VEN was administered alone. The TEAE
profile with LDX ? VXR coadministration was similar to
that seen with LDX alone. This study provides useful
information to help clinicians develop appropriate proce-
dures for dosing and safety monitoring when LDX is used
as combination therapy with VXR in an adult population.
As with each agent alone, monitoring of vital signs (e.g.,
pulse rate, blood pressure) is recommended with combi-
nation therapy of LDX and VXR.
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